IDH Mutations in Glioma Prognosis

This project seeks to comprehensively profile mutations in isocitrate dehydrogenase genes (IDH1 and IDH2) across a large spectrum of human cancers and determine their clinical significance. While IDH1/2 mutations are well recognized in gliomas and certain hematologic malignancies, their prevalence and prognostic implications across diverse tumor types remain insufficiently explored. Using genomic datasets from The Cancer Genome Atlas (TCGA) comprising 14,726 tumors across 37 cancer types, this study will evaluate the mutational distribution of IDH1 and IDH2. Further, gliomas, identified as the most frequently mutated phenotype, will be analyzed in depth using 923 cases from the Memorial Sloan Kettering Cancer Center (MSKCC) cohort to see prognostic utility.

The expected outcomes include identifying the most mutation-prone cancer phenotype, clarifying the prognostic value of IDH mutations, and uncovering their potential as therapeutic targets. This knowledge will guide precision medicine, improve diagnostic accuracy, enhance prognosis, and inform novel therapeutic strategies.